Malignant mixed müllerian tumors of the ovary: Experience with cytoreductive surgery and platinum-based combination chemotherapy

International Journal of Gynecological Cancer

Volumn 16, Issue 1, 2006, Pages 101-105

  Mok, J E ^a   Kim, Y M ^a,b   Jung, M H ^a   Kim, K R ^a   Kim, D Y ^a   Kim, J H ^a   Kim, Y T ^a   Nam, J H ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b University of Ulsan   (South Korea)

Author keywords

Cytoreductive surgery; Ovarian malignant mixed m llerian tumor; Platinum based combination chemotherapy

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; IFOSFAMIDE; PACLITAXEL; PLATINUM DERIVATIVE;

ADULT; AGED; ANEMIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CYTOREDUCTIVE SURGERY; DEMOGRAPHY; EXPERIENCE; FEMALE; HUMAN; KOREA; MINIMAL RESIDUAL DISEASE; MIXED MULLERIAN TUMOR; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; OVARY TUMOR; PANCYTOPENIA; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; SCORING SYSTEM; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IFOSFAMIDE; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MIXED TUMOR, MULLERIAN; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARIECTOMY; PROBABILITY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SAMPLING STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33645372532     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00281.x     Document Type: Review

References (23)

1. Scully RE Young RH Clement PB. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. In Rosai J ed. Atlas of tumor pathology, 3rd series, fascicle 23. Washington, DC Armed Forces Institute of Pathology 1998 128 31.
2. Dehner LP Norris HJ Taylor HB. Carcinosarcomas and mixed mesodermal tumors of the ovary. Cancer 1971 27 207 16.
3. Sit AS Price FV Kelley JL et al. Chemotherapy for malignant mixed müllerian tumors of the ovary. Gynecol Oncol 2000 79 196 200.
4. Pfeiffer P Hardt-Madsen M Rex S Holund B Bertelsen K. Malignant mixed müllerian tumors of the ovary. Report of 13 cases. Acta Obstet Gynecol Scand 1991 70 79 83.
5. Muntz HG Jones MA Goff A et al. Malignant mixed müllerian tumors of the ovary: experience with surgical cytoreduction and combination chemotherapy. Cancer 1995 76 1209 13.
6. Bicher A Levenback C Silva EG Burke TW Morris M Gershenson DM. Ovarian malignant mixed müllerian tumors treated with platinum-based chemotherapy. Obstet Gynecol 1995 85 735 9.
7. Hellstrom AC Tegerstedt G Silfversward C Pettersson F. Malignant mixed müllerian tumors of the ovary: histopathologic and clinical review of 36 cases. Int J Gynecol Cancer 1999 9 312 6.
8. Silverberg SG Major FJ Blessing JA et al. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol 1990 9 1 19.
9. Barakat RR Rubin SC Wong G Saigo PE Markman M Hoskins WJ. Mixed mesodermal tumor of the ovary: analysis of prognostic factors in 31 cases. Obstet Gynecol 1992 80 660 4.
10. Morrow CP d'Ablaing G Brady LW Blessing JA Hreshchyshyn MM. A clinical and pathologic study of 30 cases of malignant mixed müllerian epithelial and mesenchymal ovarian tumors: a Gynecologic Oncology Group study. Gynecol Oncol 1984 18 278 92.
11. Moritani S Moriya T Kushima R Sugihara H Harada M Hattori T. Ovarian carcinoma recurring as carcinosarcoma. Pathol Int 2001 51 380 4.
12. Gallardo A Matias-Guiu X Lagarda H et al. Malignant müllerian mixed tumor arising from ovarian serous carcinoma: a clinicopathologic and molecular study of two cases. Int J Gynecol Pathol 2002 21 268 72.
13. Le T Krepart GV Lotocki RJ Heywood MS. Malignant mixed mesodermal ovarian tumor treatment and prognosis: a 20-year experience. Gynecol Oncol 1997 65 237 40.
14. Boucher D Tetu B. Morphologic prognostic factors of malignant mixed müllerian tumors of the ovary: a clinicopathologic study of 15 cases. Int J Gynecol Pathol 1994 13 22 8.
15. Inthasorn P Beale P Dalrymple C Carter J. Malignant mixed müllerian tumour of the ovary: prognostic factor and response of adjuvant platinum-based chemotherapy. Aust N Z J Obstet Gynaecol 2003 43 61 4.
16. Sood AK Sorosky JI Gelder MS et al. Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction. Cancer 1998 82 1731 7.
17. Sutton GP Blessing JA Homesley HD Malfetano JH. A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol 1994 53 24 6.
18. Plaxe SC Dottino PR Goodman HM Deligdisch L Idelson M Cohen CJ. Clinical features of advanced ovarian mixed mesodermal tumors and treatment with doxorubicin- and cis-platinum-based chemotherapy. Gynecol Oncol 1990 37 244 9.
19. Baker TR Piver MS Caglar H Piedmonte M. Prospective trial of cisplatin, adriamycin, and dacarbazine in metastatic mixed mesodermal sarcomas of the uterus and ovary. Am J Clin Oncol 1991 9 246 50.
20. Simon SR Wang SE Uhl M Shackney S. Complete response of carcinosarcoma of the ovary to therapy with doxorubicin, ifosfamide and dacarbazine. Gynecol Oncol 1991 41 161 6.
21. Thigpen JT Blessing JA DeGeest K Look KY Homesley HD. Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study. Obstet Gynecol Surv 2004 59 589 90.
22. Andersen WA Young DE Peters WG 3rd. Smith EB Bagley CM Taylor PT Jr.. Platinum-based combination chemotherapy for malignant mixed mesodermal tumors of the ovary. Gynecol Oncol 1989 32 319 22.
23. Duska LR Garrett A Eltabbakh GH Oliva E Penson R Fuller AF. Paclitaxel and platinum chemotherapy for malignant mixed mullerian tumors of the ovary. Gynecol Oncol 2002 85 459 63.